ArticleRadiation oncology (London, England)2018
Short-term outcomes and clinical efficacy of stereotactic body radiation therapy (SBRT) in treatment of adrenal gland metastases from lung cancer.
Article in Radiation oncology (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Comprehensive Analysis of Lung Cancer Metastasis: Sites, Rates, Survival, and Risk Factors-A Systematic Review and Meta-Analysis.The clinical respiratory journal · 2025Pooled it
- Stereotactic Body Radiation Therapy of Adrenal Metastases: A Pooled Meta-Analysis and Systematic Review of 39 Studies with 1006 Patients.International journal of radiation oncology, biology, physics · 2020Pooled it
- Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients.Radiation oncology (London, England) · 2020Trial
- Radiotherapy for Adrenal Metastases from Hepatocellular Carcinoma: A 20-Year Bi-Institutional Experience.Current oncology (Toronto, Ont.) · 2026Article
- Efficacy of Radiotherapy for Oligometastatic Lung Cancer and Irradiation Methods Based on Metastatic Site.Cancers · 2025Review
- Total dose, fraction dose and respiratory motion management impact adrenal SBRT outcome.Clinical and translational radiation oncology · 2024Article
- Two-institution results of Stereotactic Body Radiation Therapy (SBRT) for treating adrenal gland metastases from liver cancer.BMC cancer · 2023Article
- International consensus on radiotherapy in metastatic non-small cell lung cancer.Translational lung cancer research · 2022Review
- Adrenal Gland Irradiation Causes Fatigue Accompanied by Reactive Changes in Cortisol Levels.Journal of clinical medicine · 2022Article
- Stereotactic body radiotherapy in patients with adrenal gland metastases of oligometastatic and oliogoprogressive lung cancer.Journal of radiosurgery and SBRT · 2022Article
- Stereotactic radiotherapy for adrenal oligometastases.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2022Review
- Dosimetric and biological comparisons of single planning and double plannings for bilateral lung cancer SBRT planning based on the Cyber-Knife system.Frontiers in oncology · 2022Article
- Modeling of Tumor Control Probability in Stereotactic Body Radiation Therapy for Adrenal Tumors.International journal of radiation oncology, biology, physics · 2021Review
- Rural barriers to early lung cancer detection: Exploring access to lung cancer screening programs in New Hampshire and Vermont.American journal of surgery · 2021Article
- Stereotactic body radiotherapy for adrenal oligometastasis in lung cancer patients.The British journal of radiology · 2020Article
- Single-institutional outcome-analysis of low-dose stereotactic body radiation therapy (SBRT) of adrenal gland metastases.BMC cancer · 2020Article
- Hypofractionated Radiotherapy for 35 Patients with Adrenal Metastases: A Single-Institution Experience.Cancer management and research · 2020Article
- Breath-hold versus mid-ventilation in SBRT of adrenal metastases.Technical innovations & patient support in radiation oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundTo assess the efficacy and safety of stereotactic body radiation therapy (SBRT) in the management of adrenal gland metastases (AGMs) from lung cancer. Moreover, it is the first two-institutional experience and the largest-to-date study to report the safety and efficacy of SBRT for inoperable AGM from lung cancer.
methodsIn this retrospective study, 30 patients (27 males, 3 females) with 32 AGMs were treated by SBRT from October 2006 to June 2016. Of these, 11 patients were treated with the intent of controlling all known metastatic sites and 19 for palliation of bulky AGMs. Follow-up was performed every 3 months for evaluations of efficacy and safety. Factors predictive of overall survival (OS) and local control (LC) were identified with univariate and then multivariate analysis.
resultsMedian follow-up time was 10.7 months (2.9-96.4 months). The complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) rates were 23.3%, 33.3%, 33.3% and 16.7% respectively. The 6-month, 1, and 2-year LC rates were 96.9%, 96.9%, and 72.7% respectively. Additionally, the 6-month, 1, and 2-year OS rates were 85.6%, 58.1%, and 54.0% respectively while 6-month, 1, and 2-year progression free survival (PFS) rates were 39.5%, 24.6%, and 8.2%, respectively. All the patients with cancer-induced pain (8 with abdominal pain and 6 with lumbar back pain) had significant alleviations after SBRT. The treatment was well tolerated with only 1 patient reporting grade-3 diarrhoea. No predictors of OS and LC were found after multivariate analysis, while it was demonstrated that biologic equivalent dose (BED
conclusionSBRT is a safe and effective treatment modality in the management of AGMs from lung cancer with high LC rates and acceptable toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.